A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Business description not available.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 21.5B | 21.5B | 16.5B | 14.5B | 8.4B | 10.1B |
| Net Income | 7.8B | 7.8B | 4.4B | 5.5B | 3.0B | 4.8B |
| EPS | $121.36 | $121.36 | $66.02 | $82.59 | $44.77 | $72.21 |
| Free Cash Flow | 7.6B | 7.6B | 7.0B | 3.6B | 2.0B | 6.1B |
| ROIC | 152.7% | 133.7% | 111.7% | 26.6% | 16.4% | 39.1% |
| Gross Margin | 95.4% | 95.4% | 98.6% | - | - | - |
| Debt/Equity | 0.00 | 0.10 | 0.25 | 0.04 | 0.04 | 0.04 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 6.7B | 6.7B | 5.3B | 6.3B | 3.0B | 6.3B |
| Operating Margin | 31.1% | 31.1% | 32.3% | 43.2% | 35.1% | 62.4% |
| ROE | 152.7% | 152.7% | 92.9% | 20.0% | 13.4% | 24.9% |
| Shares Outstanding | 64M | 64M | 65M | 65M | 65M | 65M |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 5.4B | 10.1B | 8.4B | 14.5B | 16.5B | 21.5B | 21.5B |
| Gross Margin | N/A | N/A | N/A | N/A | 98.6% | 95.4% | 95.4% |
| R&D | -2.4B | -3.1B | -4.2B | -5.6B | -7.6B | -9.7B | -9.7B |
| SG&A | -342M | -661M | -1.3B | -2.7B | -3.3B | -3.8B | -3.8B |
| EBIT | 2.6B | 6.3B | 3.0B | 6.3B | 5.3B | 6.7B | 6.7B |
| Op. Margin | 49.2% | 62.4% | 35.1% | 43.2% | 32.3% | 31.1% | 31.1% |
| Net Income | 2.2B | 4.8B | 3.0B | 5.5B | 4.4B | 7.8B | 7.8B |
| Net Margin | 40.4% | 47.1% | 35.1% | 37.6% | 26.4% | 36.4% | 36.4% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | 19.6% | 39.1% | 16.4% | 26.6% | 111.7% | 133.7% | 152.7% |
| ROE | 15.4% | 24.9% | 13.4% | 20.0% | 92.9% | 152.7% | 152.7% |
| ROA | N/A | 22.5% | 12.0% | 18.1% | 12.3% | 122.3% | 122.3% |
| Cash Flow | |||||||
| Op. Cash Flow | 1.3B | 6.4B | 2.2B | 3.9B | 7.4B | 7.8B | 7.8B |
| Free Cash Flow | 1.2B | 6.1B | 2.0B | 3.6B | 7.0B | 7.6B | 7.6B |
| Owner Earnings | 1.3B | 6.4B | 2.2B | 3.5B | 6.8B | 7.0B | 7.0B |
| CapEx | 79M | 307M | 252M | 317M | 366M | 187M | 187M |
| Maint. CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | N/A | N/A | N/A | 187M |
| D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx/OCF | 6.0% | 4.8% | 11.3% | 8.1% | 5.0% | 2.4% | 2.4% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 447M | 908M | 564M | 3.9B | 3.9B |
| Buyback Yield | 0.0% | 0.0% | 0.3% | 0.5% | 0.4% | 4.0% | 3.4% |
| Stock-Based Comp | N/A | N/A | N/A | 439M | 586M | 721M | 721M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | -6.5B | -8.1B | -8.9B | -1.0B | -847M | -1.4B |
| Cash & Equiv. | 3.6B | 7.3B | 9.0B | 9.9B | 2.2B | 1.4B | 1.4B |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | N/A | 0.04 | 0.04 | 0.04 | 0.25 | 0.10 | 0.00 |
| Interest Coverage | 376.9 | 4.1 | 4.2 | 2.5 | 3.3 | 3.4 | 3.4 |
| Equity | 14.0B | 19.1B | 22.1B | 27.3B | 4.7B | 5.1B | 5.1B |
| Total Assets | 0 | 21.1B | 24.6B | 30.1B | 35.3B | 6.4B | 6.4B |
| Total Liabilities | 0 | 2.0B | 2.4B | 2.8B | 3.7B | 1.3B | 1.3B |
| Intangibles | 0 | 0 | 0 | 0 | 0 | 2.1B | 2.1B |
| Retained Earnings | 0 | 7.1B | 10.0B | 14.8B | 19.0B | 3.4B | 3.4B |
| Working Capital | N/A | 17.5B | 21.2B | 26.4B | 30.7B | 3.2B | 3.2B |
| Current Assets | 0 | 18.8B | 22.7B | 28.2B | 33.1B | 3.9B | 3.9B |
| Current Liabilities | 0 | 1.3B | 1.6B | 1.8B | 2.5B | 744M | 744M |
| Per Share Data | |||||||
| EPS | 34.03 | 72.21 | 44.77 | 82.59 | 66.02 | 121.36 | 121.36 |
| Owner EPS | 21.06 | 98.70 | 34.07 | 53.11 | 104.03 | 109.84 | 109.84 |
| Book Value | 223.11 | 292.78 | 338.07 | 417.24 | 71.77 | 80.03 | 80.03 |
| Cash Flow/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 122.21 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 63.0M | 65.2M | 65.4M | 65.4M | 65.3M | 64.2M | 64.2M |
| Valuation | |||||||
| P/E Ratio | 42.9 | 33.6 | 55.2 | 37.0 | 32.6 | 12.4 | 14.7 |
| P/FCF | 73.7 | 25.8 | 81.7 | 55.5 | 20.1 | 12.8 | 15.1 |
| EV/EBIT | N/A | 24.0 | 52.0 | 30.4 | 26.3 | 14.3 | 16.9 |
| Price/Book | 6.5 | 8.3 | 7.3 | 7.3 | 30.0 | 18.8 | 22.4 |
| Price/Sales | 17.1 | 15.6 | 19.2 | 13.8 | 8.5 | 4.5 | 5.3 |
| FCF Yield | 1.4% | 3.9% | 1.2% | 1.8% | 5.0% | 7.8% | 6.6% |
| Market Cap | 92.0B | 158.1B | 161.5B | 199.6B | 140.7B | 96.8B | 114.9B |
| Avg. Price | 1,249.72 | 1,969.71 | 2,562.77 | 2,518.79 | 2,537.89 | 1,824.04 | 1,790.00 |
| Year-End Price | 1,460.50 | 2,425.00 | 2,470.00 | 3,053.00 | 2,155.00 | 1,507.50 | 1,790.00 |
Genmab A/S passes 9 of 9 quality checks, indicating strong fundamentals.
Genmab A/S trades at 14.7x trailing earnings, compared to its 15-year median P/E of 35.3x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 15.1x vs a median of 40.7x. The company's 5-year average ROIC is 65.5% with a gross margin of 97.0%. Total shareholder yield (buybacks) is 3.4%. At current prices, the estimated annualized return to fair value is +27.8%.
Genmab A/S (GMAB-CO) has a current P/E ratio of 14.7, compared to its historical median P/E of 35.3. The stock is currently considered Cheap based on its historical valuation range.
Genmab A/S (GMAB-CO) has a 5-year average return on invested capital (ROIC) of 65.5%. This indicates strong capital allocation and a potential competitive advantage.
Genmab A/S (GMAB-CO) has a market capitalization of $114.9B. It is classified as a large-cap stock.
Genmab A/S (GMAB-CO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 3.38%.
Based on historical P/E analysis, Genmab A/S (GMAB-CO) appears cheap. The current P/E of 14.7 is 58% below its historical median of 35.3. The estimated fair value CAGR (P/E method) is 18.3%.
Genmab A/S (GMAB-CO) reported annual revenue of $21.5 billion in its most recent fiscal year, based on SEC EDGAR filings.
Genmab A/S (GMAB-CO) has a net profit margin of 36.4%. This is a strong margin indicating high profitability.
Genmab A/S (GMAB-CO) generated $7.6 billion in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Genmab A/S (GMAB-CO) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
Genmab A/S (GMAB-CO) reported earnings per share (EPS) of $121.36 in its most recent fiscal year.
Genmab A/S (GMAB-CO) has a return on equity (ROE) of 152.7%. This indicates the company generates strong returns for shareholders.
Genmab A/S (GMAB-CO) has a 5-year average gross margin of 97.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Genmab A/S (GMAB-CO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Genmab A/S (GMAB-CO) has a book value per share of $80.03, based on its most recent annual SEC filing.